Antimicrobial stewardship: Impact and challenges

Clinical Therapeutics

Volumn 35, Issue 6, 2013, Pages 748-750

  Hadley, Susan ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL CLEARANCE; CONSULTATION; DRUG INDUSTRY; EDITORIAL; EMERGENCY CARE; ENTEROBACTER; ENTEROCOCCUS FAECIUM; HEALTH CARE COST; HEALTH CARE PERSONNEL; HOSPITAL INFORMATION SYSTEM; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INFECTION CONTROL PRACTITIONER; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; OSTEOMYELITIS; PATIENT CARE; PHARMACIST; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; TOTAL QUALITY MANAGEMENT; COMMUNICABLE DISEASES; DRUG USE; HOSPITAL; HOSPITAL PERSONNEL; TREATMENT OUTCOME;

ANTI-INFECTIVE AGENTS; COMMUNICABLE DISEASES; DRUG UTILIZATION REVIEW; HOSPITALS; HUMANS; PERSONNEL, HOSPITAL; TREATMENT OUTCOME;

EID: 84879456263     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.05.006     Document Type: Editorial

References (12)

1. Cosgrove S.E., Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003, 36:1433-1437.
2. McGowan J.E. Economic impact of antimicrobial resistance. Emerg Infect Dis 2001, 7:286-292.
3. Vincent J.L., Rello J., Marshall J., et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329.
4. Wenzel R.P., Bearman G., Edmond M.B. Screening for MRSA: a flawed infection control intervention. Infect Control Hosp Epidemiol 2008, 29:1012-1018.
5. Cosgrove S.E. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006, 42(Suppl 2):S82-S89.
6. Talbot G.H., Bradley J., Edwards J.E., Gilbert D., Scheld M., Bartlett J.G. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006, 42:657-668.
7. Boucher H.W., Talbott G.H., Bradley J.S., et al. Bad bugs, no drugs: no ESKAPE! an update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:1-12.
8. Dellit T.H., Owens R.C., McGowan J.E., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007, 44:159-177.
9. Doron S., Nadkarni L., Price L.L., et al. A nationwide survey of antimicrobial stewardship practices. Clin Ther 2013, 35:758-765.
10. Goff D.A., Nicolau D.P. When pharmacodynamics trumps costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobials. Clin Ther 2013, 35:766-771.
11. 24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. Clin Ther 2013, 35:772-779.
12. Rohde J.M., Jacobsen D., Rosenberg D.J. The hospitalist's role in antimicrobial stewardship: a review of work completed and description of a multisite collaborative. Clin Ther 2013, 35. 751-757.